Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers of PARP inhibitor sensitivity

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

The Original Article was published on 11 November 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Audeh MW et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737):245–251

    Article  PubMed  CAS  Google Scholar 

  2. Tutt A et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244

    Article  PubMed  CAS  Google Scholar 

  3. Sandhu SK, Wenham RM, Wilding G, McFadden M, Sun L, Toniatti C, Stroh M, Carpenter CL, De Bono JS, Schelman WR (2010) First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. J Clin Oncol 28(15s): p Abstract 3001

    Google Scholar 

  4. Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Ellisen LW, Winer EP, Goss PE (2010) A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 28(15s): p Abstract 1019

    Google Scholar 

  5. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, Huntsman D, Carmichael J, Macpherson E, Oza AM (2010) Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 28(15s): p Abstract 3002

    Google Scholar 

  6. O’Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 27(18s): p Abstract 3

  7. McCabe N et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109–8115

    Article  PubMed  CAS  Google Scholar 

  8. Farmer H et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921

    Article  PubMed  CAS  Google Scholar 

  9. Esteller M et al (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92(7):564–569

    Article  PubMed  CAS  Google Scholar 

  10. Yu PJ et al (2007) Basic fibroblast growth factor (FGF-2): the high molecular weight forms come of age. J Cell Biochem 100(5):1100–1108

    Article  PubMed  CAS  Google Scholar 

  11. Mendes-Pereira AM et al (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1(6–7):315–322

    Article  PubMed  CAS  Google Scholar 

  12. Schaffner C et al (1999) Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94(2):748–753

    PubMed  CAS  Google Scholar 

  13. Stilgenbauer S et al (1997) Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3(10):1155–1159

    Article  PubMed  CAS  Google Scholar 

  14. Wen Q et al (2008) A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol Biol Cell 19(4):1693–1705

    Article  PubMed  CAS  Google Scholar 

  15. Olopade OI, Wei M (2003) FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 3(5):417–420

    Article  PubMed  CAS  Google Scholar 

  16. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819

    Article  PubMed  CAS  Google Scholar 

  17. Brustmann H (2007) Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol 26(2):147–153

    PubMed  Google Scholar 

  18. Bartkova J et al (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444(7119):633–637

    Article  PubMed  CAS  Google Scholar 

  19. Weigelt B et al (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 11(4):339–349

    Article  PubMed  CAS  Google Scholar 

  20. von Minckwitz G, Müller B, Loibl S, Blohmer JU, duBois A, Huober J, Kandolf R, Budcizes J, Denkert C (2010) PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy. Eur J Cancer Suppl 8:188

    Google Scholar 

  21. Loibl S, Müller B, Von Minckwitz G, Blohmer JU, Bois Ad, Huober JB, Fend F, Budczies J, Denkert C (2010) PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. J Clin Oncol 28(15s): p Abstract 10511

  22. Gottipati P et al (2010) Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70(13):5389–5398

    Article  PubMed  CAS  Google Scholar 

  23. Zaremba T et al (2009) Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer 101(2):256–262

    Article  PubMed  CAS  Google Scholar 

  24. Yang SX et al (2009) Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther 8(21):2004–2009

    Article  PubMed  CAS  Google Scholar 

  25. Konstantinopoulos PA et al (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28(22):3555–3561

    Article  PubMed  CAS  Google Scholar 

  26. Rodriguez AA et al (2010) DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 123(1):189–196

    Article  PubMed  CAS  Google Scholar 

  27. Holstege H et al (2009) High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69(8):3625–3633

    Article  PubMed  CAS  Google Scholar 

  28. Silver DP et al (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145–1153

    Article  PubMed  CAS  Google Scholar 

  29. Godon C et al (2008) PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 36(13):4454–4464

    Article  PubMed  CAS  Google Scholar 

  30. Bryant HE et al (2009) PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 28(17):2601–2615

    Article  PubMed  CAS  Google Scholar 

  31. Swisher EM et al (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68(8):2581–2586

    Article  PubMed  CAS  Google Scholar 

  32. Edwards SL et al (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182):1111–1115

    Article  PubMed  CAS  Google Scholar 

  33. Fong PC et al (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28(15):2512–2519

    Article  PubMed  CAS  Google Scholar 

  34. Bouwman P et al (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17(6):688–695

    Article  PubMed  CAS  Google Scholar 

  35. Bunting SF et al (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141(2):243–254

    Article  PubMed  CAS  Google Scholar 

  36. Schild D, Wiese C (2010) Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 38(4):1061–1070

    Article  PubMed  CAS  Google Scholar 

  37. Gonçalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg J-P, Chaffanet M, Viens P, Birnbaum D, Bertucci F (2010) Poly(ADP- ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat. doi: 10.1007/s10549-010-1199-y

    PubMed  Google Scholar 

Download references

Conflict of interest

Professor Ashworth may benefit financially from the development of PARP inhibitors through patents held jointly with AstraZeneca through the Institute of Cancer Research ‘rewards to inventors’ scheme.

Author information

Authors and Affiliations

  1. Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK

    Nicholas C. Turner & Alan Ashworth

  2. Breast Unit, Royal Marsden Hospital, London, SW3 6JJ, UK

    Nicholas C. Turner

Authors
  1. Nicholas C. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Ashworth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan Ashworth.

Additional information

This is an invited commentary to article doi: 10.1007/s10549-010-1199-y.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turner, N.C., Ashworth, A. Biomarkers of PARP inhibitor sensitivity. Breast Cancer Res Treat 127, 283–286 (2011). https://doi.org/10.1007/s10549-011-1375-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1375-8

Keywords

Search

Navigation